VRTX
NASDAQ · Biotechnology
Vertex Pharmaceuticals Inc
$508.33
-8.11 (-1.57%)
VRTX News9 articles
Sionna Plunges 91% as CF Drug Fails Trial, Market Cap Drops Below Cash
Sionna shares fell 91% after its CF drug SION-719 failed a Phase 2a trial, with efficacy far below expectations. The stock now trades below cash value.
Sionna Therapeutics Collapses 92% After Phase 2a Setback
Sionna Therapeutics (SION) tumbled 92% after its Phase 2a trial failed to meet the primary endpoint, pushing the market cap below its cash holdings. Vertex (VRTX) rose on reduced competitive risk.
AbCellera Shares Jump 9.7% Ahead of Key Phase 2 Data Release
AbCellera (ABCL) rose 9.7% after hours as investors await Phase 2 data for ABCL635, set to release Monday. The surge adds ~$205M to market cap.
Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb
Vertex Pharmaceuticals raised its 2026 outlook after strong Q2, but non-CF drugs Casgevy and Journavx face a 53% H2 growth hurdle.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Vertex's $10B Cash Deal Narrows Crinetics' Merger Spread
Crinetics shares traded at $83.60 premarket, just 1.7% below Vertex's $85 cash offer, as the $10 billion deal shifts focus from biotech fundamentals to merger arbitrage.
Forgent Power Soars on Record Orders, AI Data Center Demand Drives Growth
Forgent Power Solutions raised its FY2026 revenue forecast after record Q3 bookings of $867 million, signaling robust AI data center demand. Shares jumped in premarket trading.
Vertex Shares Slide on Updated Safety Warnings for CF Drugs
Vertex Pharmaceuticals shares declined 4.6% to $433.07 following updated U.S. safety labels for its cystic fibrosis drugs citing serious neuropsychiatric events. The company maintains its 2026 revenue outlook remains heavily dependent on CF treatments.
Vertex Shares Surge on Analyst Upgrade, Pipeline Expansion in Focus
Vertex Pharmaceuticals shares climbed 5.7% following an upgrade from Oppenheimer, driven by its 2026 revenue outlook and expanding pipeline in gene-editing, pain, and kidney therapies.